Sponsored

Cynata’s (ASX: CYP) data on consistency of Cymerus™ MSCs released at leading Stem Cell Research Conference

November 16, 2022 12:34 PM IST | By Aditi Sarkar
 Cynata’s (ASX: CYP) data on consistency of Cymerus™ MSCs released at leading Stem Cell Research Conference
Image source: © Yur4you | Megapixl.com

Highlights

  • Data demonstrating the consistency of Cynata’s Cymerus™ MSCs has been presented at a leading Stem Cell Research Conference held in Melbourne.
  • The study further validates the potential of Cymerus MSCs as an off-the-shelf cell therapy.
  • The major findings of the study include:
    • Cymerus™ MSCs exhibit less batch-to-batch heterogeneity (variability) than tissue-derived MSCs.
    • Cymerus™ MSCs also exhibit significantly less variability within each batch.

Cynata Therapeutics (ASX:CYP), a clinical-stage cell therapeutics company, announced the conference presentation of data from a study on the consistency of Cymerus™ mesenchymal stem cells (MSCs) and MSCs derived from various tissue sources.  Manufacturing consistency is an absolute requirement in the manufacture of pharmaceutical products, so these findings confirm an important competitive advantage of Cymerus MSCs compared with MSCs derived from donor tissues.

The study endorses the potential of Cymerus MSCs as an off-the-shelf cell therapy. It also offers a better insight into the sources of MSC variability to have more predictable clinical outcomes.

The data was presented at the Biennial Australasian Society for Stem Cell Research (ASSCR) and Australasian Gene and Cell Therapy Society (AGCTS) Scientific Meeting in Melbourne.

Below are the major findings of the study

© 2022 Kalkine Media®, Data source: Company update

The study, carried out at Monash University by a team of scientists led by Associate Professor Jess Frith, compared the consistency of different batches of MSCs. It included Cymerus™ induced pluripotent stem cell (iPSC)-derived MSCs and tissue-derived MSCs from adipose tissue, bone marrow and umbilical cord.

The next-generation single-cell sequencing technique was used to profile the gene expression of the different MSCs at the individual cell level.

© 2022 Kalkine Media®, Data and image source: Company update

At the time of writing this article, share price of Cynata was AU$0.305 apiece.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.